Correlation of Urinary Bisphenol A and Phthalates With Overweight and Obesity in Children

Shravani G U1, Sunil Kumar B M1, Manjunath P R2

  • 1Pediatrics, M. S. Ramaiah University of Applied Sciences, Bangalore, IND.

Cureus
|April 17, 2026
PubMed

Insights

Higher urinary levels of Bisphenol A (BPA) and phthalates were found in overweight or obese Indian children. These endocrine-disrupting chemicals may contribute to childhood obesity, emphasizing the need to reduce plastic exposure.

Area of Science:

  • Environmental Health
  • Pediatric Endocrinology
  • Toxicology

Background:

  • Bisphenol A (BPA) and phthalates are common endocrine-disrupting chemicals (EDCs) found in consumer products.
  • EDCs may disrupt hormonal regulation and metabolic processes, potentially contributing to childhood obesity.
  • Understanding EDC exposure in relation to pediatric weight status is crucial for public health.

Purpose of the Study:

  • To quantify urinary Bisphenol A (BPA) and phthalate concentrations in normal-weight versus overweight/obese Indian children.
  • To investigate correlations between urinary EDC levels and anthropometric measures of adiposity.
  • To assess the association between EDCs and childhood obesity in a South Asian population.

Main Methods:

  • A prospective observational study involving 90 children (2-18 years) in Bangalore, India.
  • Urine samples analyzed for BPA and phthalates using enzyme-linked immunosorbent assay (ELISA).
  • Comparison of EDC levels and anthropometric data (BMI, waist circumference, etc.) between normal-weight and overweight/obese groups.

Main Results:

  • Significantly higher mean urinary BPA and phthalate levels in overweight/obese children compared to controls (p < 0.001).
  • Positive correlations observed between raw urinary BPA/phthalate levels and BMI, waist circumference, and triceps skinfold thickness.
  • Creatinine-corrected EDC levels were also elevated in the overweight/obese cohort.

Conclusions:

  • Urinary BPA and phthalate concentrations are significantly associated with overweight and obesity in Indian children.
  • Findings support the role of EDCs as potential obesogens in pediatric populations.
  • Public health strategies to minimize children's exposure to plastics and associated chemicals are warranted.

Related Concept Videos

Drug Dosing: Obese Patients01:21

Drug Dosing: Obese Patients

In the United States, obesity is a prominent concern. It is linked to heightened mortality rates due to increased occurrences of conditions such as hypertension, atherosclerosis, coronary artery disease, and diabetes compared to nonobese individuals. A patient is classified as obese if their actual body weight surpasses the ideal or desirable body weight by 20%, based on Metropolitan Life Insurance Company data. Ideal body weights consider average weights and heights for males and females...
350
Obesity01:24

Obesity

The Body Mass Index (BMI) is a numerical value derived from a person's weight and height, used to categorize individuals into weight ranges. It is calculated using the formula: weight in kilograms divided by height in meters squared. Obesity is a health condition characterized by excessive accumulation of adipose tissue that poses health risks, often diagnosed with a BMI ≥ 30. This excess fat storage occurs when surplus dietary calories are converted into triglycerides and stored in...
1.6K
Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion01:20

Pharmacokinetics in Obese Patients: Drug Metabolism and Excretion

Drug metabolism, a critical process in the liver, involves two primary phases: Phase I reactions and Phase II conjugation. Obesity introduces significant alterations in this metabolic process, primarily due to fatty infiltration of the liver, leading to conditions such as nonalcoholic fatty liver disease (NAFLD). This condition can modify the activities of both Phase I and II enzymes, impacting how drugs are metabolized in obese patients.Phase I metabolism sees variable effects across...
309
Pharmacokinetics in Obese Patients: Drug Absorption and Distribution01:25

Pharmacokinetics in Obese Patients: Drug Absorption and Distribution

Obesity significantly alters the pharmacokinetic processes of drug absorption and distribution, presenting unique challenges in medical treatment. The increased fat tissue and decreased lean muscle in obese individuals can significantly affect how drugs are absorbed into the body and distributed across different tissues. This alteration can lead to variances in the effectiveness and safety of medications, necessitating adjustments in dosing or drug selection for obese patients.One notable...
423
Pharmacokinetics in Pediatric Patients: Drug Distribution01:17

Pharmacokinetics in Pediatric Patients: Drug Distribution

Drug distribution in the pediatric population exhibits unique challenges and considerations due to the physiological differences between children, particularly neonates and infants, and adults. A crucial aspect of pediatric pharmacology is understanding how these differences impact the pharmacokinetics of various drugs, necessitating age-specific dosing strategies to ensure efficacy and safety.Neonates and infants have a higher total body water content, ~75%–90% of their body weight,...
508
Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption01:23

Pharmacokinetics in Pediatric Patients: Overview and Drug Absorption

Understanding the physiological differences in the pediatric population is crucial for effective pharmacotherapy. Neonates, infants, and children exhibit significant variations in gastric pH, gastric emptying time, intestinal transit time, and biliary function. These variations profoundly affect oral drug absorption, necessitating a nuanced approach to pediatric dosing.Neonates present with a unique physiological profile, having a gastric pH greater than 4 and faster and more irregular gastric...
882